Monoklonális antitestek a non-Hodgkin-lymphomák kezelésében

Research output: Article

Abstract

Ninety percent of non-Hodgkin-lymphomas are of B-cell phenotype. The availability of monoclonal antibodies in their treatment is of fundamental importance. Rituximab was the first monoclonal antibody approved by the FDA. Rituximab is a monoclonal antibody against the CD20 antigen, approved by the FDA originally for the treatment of relapsing or refractory low grade (indolent) or follicular non-Hodgkin-lymphoma. Nevertheless, rituximab achieved its most basic success not in follicular lymphoma, but - when combined with chemotherapy- in diffuse large B-cell lymphoma. Since the availability of rituximab, treatment results have improved in virtually all B-cell lymphoma subtypes. Conjugation of the antiCD20 monoclonal antibody with a radioisotope is a step by which not only the CD20+ tumor cells, but also the neighbouring CD20- negative tumour cells are destructed. Ibritumomab tiuxetan (Zevalin) has been approved originally for relapsing or treatmentresistant follicular lymphoma, but now it can be given already as consolidation treatment following remission induction in previously untreated follicular lymphoma patients as well. Chronic lymphocytic leukemia belongs to the low grade non-Hodgkin-lymphomas. In this disorder prognosis greatly depends on the intrinsic genetical characteristics of the disease. Treatment with purine nucleoside analogues certainly is a step forward as compared with alkylating agents, but these drugs did not improve overall survival. Monoclonal antibodies open a new era in the treatment of CLL patients. Alemtuzumab (monoclonal anti-CD52 antibody) is suitable for the treatment of those CLL patients, whose disease is resistant to purin nucleoside analogues because of certain genetical characteristics of the disease. According to the newest results completion of the standard fludarabin-cytoxan chemotherapy with rituximab offers survival advantage for our CLL patients.

Original languageHungarian
Pages (from-to)213-222
Number of pages10
JournalOrvoskepzes
Volume84
Issue number3
Publication statusPublished - 2009

Fingerprint

Non-Hodgkin's Lymphoma
Monoclonal Antibodies
Follicular Lymphoma
Therapeutics
CD20 Antigens
Purine Nucleosides
Remission Induction
Drug Therapy
Survival
Lymphoma, Large B-Cell, Diffuse
Alkylating Agents
B-Cell Lymphoma
B-Cell Chronic Lymphocytic Leukemia
Nucleosides
Radioisotopes
Cyclophosphamide
Anti-Idiotypic Antibodies
Neoplasms
B-Lymphocytes
Rituximab

Keywords

  • Alemtuzumab
  • Diffúz large B-cell lymphoma
  • Follicular lymphoma
  • Rituximab
  • Zevalin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Monoklonális antitestek a non-Hodgkin-lymphomák kezelésében. / Demeter, J.

In: Orvoskepzes, Vol. 84, No. 3, 2009, p. 213-222.

Research output: Article

@article{31a82d0b6fb84dc0aa92ce554236477e,
title = "Monoklon{\'a}lis antitestek a non-Hodgkin-lymphom{\'a}k kezel{\'e}s{\'e}ben",
abstract = "Ninety percent of non-Hodgkin-lymphomas are of B-cell phenotype. The availability of monoclonal antibodies in their treatment is of fundamental importance. Rituximab was the first monoclonal antibody approved by the FDA. Rituximab is a monoclonal antibody against the CD20 antigen, approved by the FDA originally for the treatment of relapsing or refractory low grade (indolent) or follicular non-Hodgkin-lymphoma. Nevertheless, rituximab achieved its most basic success not in follicular lymphoma, but - when combined with chemotherapy- in diffuse large B-cell lymphoma. Since the availability of rituximab, treatment results have improved in virtually all B-cell lymphoma subtypes. Conjugation of the antiCD20 monoclonal antibody with a radioisotope is a step by which not only the CD20+ tumor cells, but also the neighbouring CD20- negative tumour cells are destructed. Ibritumomab tiuxetan (Zevalin) has been approved originally for relapsing or treatmentresistant follicular lymphoma, but now it can be given already as consolidation treatment following remission induction in previously untreated follicular lymphoma patients as well. Chronic lymphocytic leukemia belongs to the low grade non-Hodgkin-lymphomas. In this disorder prognosis greatly depends on the intrinsic genetical characteristics of the disease. Treatment with purine nucleoside analogues certainly is a step forward as compared with alkylating agents, but these drugs did not improve overall survival. Monoclonal antibodies open a new era in the treatment of CLL patients. Alemtuzumab (monoclonal anti-CD52 antibody) is suitable for the treatment of those CLL patients, whose disease is resistant to purin nucleoside analogues because of certain genetical characteristics of the disease. According to the newest results completion of the standard fludarabin-cytoxan chemotherapy with rituximab offers survival advantage for our CLL patients.",
keywords = "Alemtuzumab, Diff{\'u}z large B-cell lymphoma, Follicular lymphoma, Rituximab, Zevalin",
author = "J. Demeter",
year = "2009",
language = "Hungarian",
volume = "84",
pages = "213--222",
journal = "Orvoskepzes",
issn = "0030-6037",
publisher = "Semmelweis Kiado",
number = "3",

}

TY - JOUR

T1 - Monoklonális antitestek a non-Hodgkin-lymphomák kezelésében

AU - Demeter, J.

PY - 2009

Y1 - 2009

N2 - Ninety percent of non-Hodgkin-lymphomas are of B-cell phenotype. The availability of monoclonal antibodies in their treatment is of fundamental importance. Rituximab was the first monoclonal antibody approved by the FDA. Rituximab is a monoclonal antibody against the CD20 antigen, approved by the FDA originally for the treatment of relapsing or refractory low grade (indolent) or follicular non-Hodgkin-lymphoma. Nevertheless, rituximab achieved its most basic success not in follicular lymphoma, but - when combined with chemotherapy- in diffuse large B-cell lymphoma. Since the availability of rituximab, treatment results have improved in virtually all B-cell lymphoma subtypes. Conjugation of the antiCD20 monoclonal antibody with a radioisotope is a step by which not only the CD20+ tumor cells, but also the neighbouring CD20- negative tumour cells are destructed. Ibritumomab tiuxetan (Zevalin) has been approved originally for relapsing or treatmentresistant follicular lymphoma, but now it can be given already as consolidation treatment following remission induction in previously untreated follicular lymphoma patients as well. Chronic lymphocytic leukemia belongs to the low grade non-Hodgkin-lymphomas. In this disorder prognosis greatly depends on the intrinsic genetical characteristics of the disease. Treatment with purine nucleoside analogues certainly is a step forward as compared with alkylating agents, but these drugs did not improve overall survival. Monoclonal antibodies open a new era in the treatment of CLL patients. Alemtuzumab (monoclonal anti-CD52 antibody) is suitable for the treatment of those CLL patients, whose disease is resistant to purin nucleoside analogues because of certain genetical characteristics of the disease. According to the newest results completion of the standard fludarabin-cytoxan chemotherapy with rituximab offers survival advantage for our CLL patients.

AB - Ninety percent of non-Hodgkin-lymphomas are of B-cell phenotype. The availability of monoclonal antibodies in their treatment is of fundamental importance. Rituximab was the first monoclonal antibody approved by the FDA. Rituximab is a monoclonal antibody against the CD20 antigen, approved by the FDA originally for the treatment of relapsing or refractory low grade (indolent) or follicular non-Hodgkin-lymphoma. Nevertheless, rituximab achieved its most basic success not in follicular lymphoma, but - when combined with chemotherapy- in diffuse large B-cell lymphoma. Since the availability of rituximab, treatment results have improved in virtually all B-cell lymphoma subtypes. Conjugation of the antiCD20 monoclonal antibody with a radioisotope is a step by which not only the CD20+ tumor cells, but also the neighbouring CD20- negative tumour cells are destructed. Ibritumomab tiuxetan (Zevalin) has been approved originally for relapsing or treatmentresistant follicular lymphoma, but now it can be given already as consolidation treatment following remission induction in previously untreated follicular lymphoma patients as well. Chronic lymphocytic leukemia belongs to the low grade non-Hodgkin-lymphomas. In this disorder prognosis greatly depends on the intrinsic genetical characteristics of the disease. Treatment with purine nucleoside analogues certainly is a step forward as compared with alkylating agents, but these drugs did not improve overall survival. Monoclonal antibodies open a new era in the treatment of CLL patients. Alemtuzumab (monoclonal anti-CD52 antibody) is suitable for the treatment of those CLL patients, whose disease is resistant to purin nucleoside analogues because of certain genetical characteristics of the disease. According to the newest results completion of the standard fludarabin-cytoxan chemotherapy with rituximab offers survival advantage for our CLL patients.

KW - Alemtuzumab

KW - Diffúz large B-cell lymphoma

KW - Follicular lymphoma

KW - Rituximab

KW - Zevalin

UR - http://www.scopus.com/inward/record.url?scp=82455216847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82455216847&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:82455216847

VL - 84

SP - 213

EP - 222

JO - Orvoskepzes

JF - Orvoskepzes

SN - 0030-6037

IS - 3

ER -